BR112023003427A2 - Terapia com antagonista de lag-3 para carcinoma hepatocelular - Google Patents
Terapia com antagonista de lag-3 para carcinoma hepatocelularInfo
- Publication number
- BR112023003427A2 BR112023003427A2 BR112023003427A BR112023003427A BR112023003427A2 BR 112023003427 A2 BR112023003427 A2 BR 112023003427A2 BR 112023003427 A BR112023003427 A BR 112023003427A BR 112023003427 A BR112023003427 A BR 112023003427A BR 112023003427 A2 BR112023003427 A2 BR 112023003427A2
- Authority
- BR
- Brazil
- Prior art keywords
- lag
- hepatocellular carcinoma
- antagonist therapy
- antagonist
- therapy
- Prior art date
Links
- 102000017578 LAG3 Human genes 0.000 title abstract 3
- 101150030213 Lag3 gene Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
TERAPIA COM ANTAGONISTA DE LAG-3 PARA CARCINOMA HEPATOCELULAR. A presente invenção refere-se a um método de tratamento de um carcinoma hepatocelular com um antagonista de LAG-3 sozinho ou em combinação com um agente terapêutico adicional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063071698P | 2020-08-28 | 2020-08-28 | |
US202163144174P | 2021-02-01 | 2021-02-01 | |
PCT/US2021/048002 WO2022047189A1 (en) | 2020-08-28 | 2021-08-27 | Lag-3 antagonist therapy for hepatocellular carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023003427A2 true BR112023003427A2 (pt) | 2023-03-21 |
Family
ID=78086031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023003427A BR112023003427A2 (pt) | 2020-08-28 | 2021-08-27 | Terapia com antagonista de lag-3 para carcinoma hepatocelular |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230265188A1 (pt) |
EP (1) | EP4204095A1 (pt) |
JP (1) | JP2023540255A (pt) |
KR (1) | KR20230058442A (pt) |
AU (1) | AU2021331476A1 (pt) |
BR (1) | BR112023003427A2 (pt) |
CA (1) | CA3193421A1 (pt) |
IL (1) | IL300813A (pt) |
MX (1) | MX2023002332A (pt) |
WO (1) | WO2022047189A1 (pt) |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
OA11917A (en) | 1998-12-23 | 2006-04-13 | Abgenix Inc | Human monoclonal antibodies to ctla-4. |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
BRPI0408116B1 (pt) | 2003-03-05 | 2022-09-20 | Halozyme, Inc | Polipeptídeos de hialuronidase solúveis conjugados a polímero, composições farmacêuticas compreendendo polipeptídeos ph20 solúveis, seus usos e processo de preparação, e ácidos nucléicos que codificam polipeptídeos de hialuronidase solúveis |
DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
CA2855098C (en) | 2007-06-18 | 2018-02-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
JP6322413B2 (ja) | 2011-03-10 | 2018-05-09 | プロヴェクタス ファーマテック,インク. | 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ |
HUE037651T2 (hu) | 2011-04-20 | 2018-09-28 | Medimmune Llc | B7-Hl-et és PD-l-et kötõ ellenanyagok és más molekulák |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
CA3175758A1 (en) | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
PL2970464T3 (pl) | 2013-03-15 | 2020-10-05 | Glaxosmithkline Intellectual Property Development Limited | Wiążące białka anty-lag-3 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
DK2992017T3 (da) | 2013-05-02 | 2021-01-25 | Anaptysbio Inc | Antistoffer rettet mod programmeret død-1 (pd-1) |
US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
EA029901B1 (ru) | 2013-09-04 | 2018-05-31 | Бристол-Майерс Сквибб Компани | Соединения для применения в качестве иммуномодуляторов |
HUE049281T2 (hu) | 2013-09-13 | 2020-09-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
AU2014323523B2 (en) | 2013-09-20 | 2020-02-20 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
KR20220126813A (ko) | 2014-03-14 | 2022-09-16 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
EP3144388B1 (en) | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
CN106999536B (zh) | 2014-09-11 | 2020-11-27 | 百时美施贵宝公司 | Pd-1/pd-l1及cd80(b7-1)/pd-l1蛋白质/蛋白质相互作用的大环抑制剂 |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
ES2881484T3 (es) | 2014-12-22 | 2021-11-29 | Pd 1 Acquisition Group Llc | Anticuerpos anti-PD-1 |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
KR20170135860A (ko) | 2015-03-13 | 2017-12-08 | 싸이톰스 테라퓨틱스, 인크. | 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법 |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
LT3303394T (lt) | 2015-05-29 | 2020-10-12 | Agenus Inc. | Anti-ctla-4 antikūnai ir jų naudojimo būdai |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
US9902772B2 (en) | 2015-07-22 | 2018-02-27 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind LAG3 |
PL3317301T3 (pl) | 2015-07-29 | 2021-11-15 | Novartis Ag | Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3 |
KR20180093127A (ko) | 2015-07-30 | 2018-08-20 | 마크로제닉스, 인크. | Pd-1-결합 분자 및 그것의 사용 방법 |
WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
WO2017025498A1 (en) | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
KR102055396B1 (ko) | 2015-08-11 | 2019-12-12 | 우시 바이올로직스 (케이만) 인코포레이티드 | 신규한 항-pd-1 항체 |
WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
PE20181322A1 (es) | 2015-09-01 | 2018-08-14 | Agenus Inc | Anticuerpo anti-pd1 y sus metodos de uso |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
JP6925278B2 (ja) | 2015-11-18 | 2021-08-25 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
AU2016355570B2 (en) | 2015-11-18 | 2020-01-02 | Merck Sharp & Dohme Llc | PD1 and/or LAG3 binders |
CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技(上海)有限公司 | 抗pd-1抗体及其治疗用途 |
WO2017087901A2 (en) | 2015-11-19 | 2017-05-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
JP7082051B2 (ja) | 2016-01-11 | 2022-06-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 抗原特異的cd8+t細胞の産生におけるインターロイキン-10及びその使用方法 |
WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
WO2017132825A1 (zh) | 2016-02-02 | 2017-08-10 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
PL3458478T3 (pl) | 2016-05-18 | 2021-06-28 | Boehringer Ingelheim International Gmbh | Przeciwciała anty pd-1 i anty-lag3 do leczenia nowotworu |
BR112018076525A2 (pt) | 2016-06-20 | 2019-04-02 | F-Star Beta Limited | membros de ligação a lag-3 |
PL3472207T3 (pl) | 2016-06-20 | 2021-07-12 | F-Star Delta Limited | Wiążące cząsteczki wiążące się z PD-L1 i LAG-3 |
JP6998895B2 (ja) | 2016-06-23 | 2022-01-18 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Lag-3抗体、その抗原結合フラグメント、およびそれらの医薬的用途 |
MA45591A (fr) | 2016-07-08 | 2021-05-26 | Bristol Myers Squibb Co | Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs |
KR102340687B1 (ko) | 2016-08-15 | 2021-12-16 | 국립대학법인 홋가이도 다이가쿠 | 항 lag-3 항체 |
US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
US10844119B2 (en) | 2016-10-11 | 2020-11-24 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
UA127050C2 (uk) | 2016-10-13 | 2023-03-29 | Чіа Тай Тяньцин Фармасьютікал Груп Ко., Лтд. | Ahtи-lag-3 антитіло i композиція, що містить його |
UY37463A (es) | 2016-11-02 | 2018-05-31 | Glaxosmithkline Ip No 2 Ltd | Proteínas de unión |
KR102526034B1 (ko) | 2016-11-07 | 2023-04-25 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
CN110072860B (zh) | 2016-12-20 | 2022-09-02 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
WO2018152687A1 (en) * | 2017-02-22 | 2018-08-30 | I-Mab | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
WO2018183171A1 (en) | 2017-03-27 | 2018-10-04 | Bristol-Myers Squibb Company | Substituted isoquionline derivatives as immunomudulators |
KR102408873B1 (ko) | 2017-04-05 | 2022-06-15 | 에프. 호프만-라 로슈 아게 | Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체 |
PL3606954T3 (pl) | 2017-04-05 | 2022-10-17 | F. Hoffmann-La Roche Ag | Przeciwciała anty-LAG3 |
JP2020517695A (ja) | 2017-04-27 | 2020-06-18 | テサロ, インコーポレイテッド | リンパ球活性化遺伝子−3(lag−3)に対する抗体薬およびそれらの使用 |
AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
EP3621642A4 (en) | 2017-05-10 | 2021-01-06 | Centrymed Pharmaceutical Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES |
WO2018217940A2 (en) | 2017-05-24 | 2018-11-29 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
BR112019020610A2 (pt) * | 2017-05-30 | 2020-04-22 | Bristol-Myers Squibb Company | tratamento de tumores positivos para o lag-3 |
US11066445B2 (en) | 2017-06-23 | 2021-07-20 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of PD-1 |
CN110914303B (zh) | 2017-07-13 | 2023-06-02 | 南京维立志博生物科技有限公司 | 结合lag-3的抗体及其用途 |
CA3070095A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
KR20200058506A (ko) | 2017-10-03 | 2020-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
WO2019147662A1 (en) | 2018-01-23 | 2019-08-01 | Bristol-Myers Squibb Company | 2,8-diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators |
ES2933601T3 (es) | 2018-03-01 | 2023-02-10 | Bristol Myers Squibb Co | Compuestos útiles como inmunomoduladores |
JP2021527082A (ja) * | 2018-06-11 | 2021-10-11 | イェール ユニバーシティーYale University | 新規な免疫チェックポイント阻害剤 |
-
2021
- 2021-08-27 IL IL300813A patent/IL300813A/en unknown
- 2021-08-27 WO PCT/US2021/048002 patent/WO2022047189A1/en active Application Filing
- 2021-08-27 AU AU2021331476A patent/AU2021331476A1/en active Pending
- 2021-08-27 CA CA3193421A patent/CA3193421A1/en active Pending
- 2021-08-27 EP EP21789895.6A patent/EP4204095A1/en active Pending
- 2021-08-27 US US18/043,562 patent/US20230265188A1/en active Pending
- 2021-08-27 JP JP2023513856A patent/JP2023540255A/ja active Pending
- 2021-08-27 KR KR1020237009984A patent/KR20230058442A/ko unknown
- 2021-08-27 MX MX2023002332A patent/MX2023002332A/es unknown
- 2021-08-27 BR BR112023003427A patent/BR112023003427A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
US20230265188A1 (en) | 2023-08-24 |
KR20230058442A (ko) | 2023-05-03 |
AU2021331476A9 (en) | 2023-07-06 |
MX2023002332A (es) | 2023-03-21 |
IL300813A (en) | 2023-04-01 |
CA3193421A1 (en) | 2022-03-03 |
JP2023540255A (ja) | 2023-09-22 |
AU2021331476A1 (en) | 2023-05-04 |
EP4204095A1 (en) | 2023-07-05 |
WO2022047189A1 (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
PH12018500642A1 (en) | Anti-garp antibody | |
BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
BR112016004118A2 (pt) | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
BR112021018739A2 (pt) | Composições e métodos para o tratamento de doenças ou distúrbios associados a kras | |
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
BR112015018549A8 (pt) | métodos de tratamento de deficiência de ferro | |
BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
BR112022023048A2 (pt) | Tratamento de combinação de distúrbios hepáticos | |
BR112019004684A2 (pt) | combinação de agonistas de fxr | |
BR112019009726A2 (pt) | terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica | |
BR112019008241A2 (pt) | tratamento do prurigo nodular | |
BR112014013709A2 (pt) | Métodos, composições farmaceuticas, e kits, para tratar cânceres resitentes às antiprogestinas |